Testing ELA026 for T/NK cell cancers that returned or didn't respond
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests an investigational drug called ELA026 for people with T-cell or NK-cell cancers that came back or didn't get better after prior treatment. The goal is to see if ELA026 can help shrink the cancer or slow its growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a type of T-cell or NK-cell cancer that came back or didn't respond to at least one prior treatment (for CTCL, you need at least two prior treatments)
- Your cancer is measurable on scans or in bone marrow
- You are generally able to care for yourself (ECOG performance score 0-2)
- Your doctor expects you to live more than 6 months
- You are not planning to get pregnant or father a child during the study and for 2 months after the last dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using immune cells (CAR-NK) made from donated cord blood. These cells are designed to find and attack T-cell lymphoma that has come back or not responded to other treatments. The goal is to see if this approach is safe and effective.
This early-phase trial tests an injected “CAR T” cell therapy made to attack CD19-positive blood cancers that have come back or did not respond. If you qualify, the study checks whether the treatment can help control the cancer and is safe enough to study further.
This study tests a new drug called KK2223 for people with certain types of T-cell lymphoma (PTCL or CTCL) that have not responded to previous treatments. The goal is to find out if the drug is safe and if it helps shrink or control the lymphoma.
This trial tests a new cell therapy (TCR-T cells) for people with EBV-positive lymphoma that has not responded to standard treatments or has come back. The therapy uses your own immune cells that have been specially trained to find and attack cancer cells carrying the EBV virus.
This trial tests a new drug called CTD402 for people with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) that has come back or not gone away after treatment. The goal is to see if CTD402 can help reduce or eliminate the cancer cells in the bone marrow.
This trial tests a new drug called GCC2005 for people with certain types of NK or T-cell cancers that have come back or not responded to at least two previous treatments. The goal is to see if it is safe and if it can help shrink tumors.
Hear when a new T-cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.